NS Pharma Limited

	Page
Balance Sheet	1—2
Notes to the Financial Statements	3—5

Registered number: 09792259

		2024		2023
	Notes	£	£	£	£
FIXED ASSETS
Intangible Assets	4		100,000		150,000

			100,000		150,000
CURRENT ASSETS
Stocks	5	50,570		42,570
Debtors	6	80,143		79,679
Cash at bank and in hand		49		61

		130,762		122,310
Creditors: Amounts Falling Due Within One Year	7	(207,009 )		(193,099 )

NET CURRENT ASSETS (LIABILITIES)			(76,247 )		(70,789 )

TOTAL ASSETS LESS CURRENT LIABILITIES			23,753		79,211

Creditors: Amounts Falling Due After More Than One Year	8		(374,327 )		(374,327 )

NET LIABILITIES			(350,574 )		(295,116 )

CAPITAL AND RESERVES
Called up share capital	9		2		2
Profit and Loss Account			(350,576 )		(295,118 )

SHAREHOLDERS' FUNDS			(350,574)		(295,116)

Page 1

Page 2

NS Pharma Limited

Balance Sheet (continued)

As At 30 September 2024

For the year ending 30 September 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The member has not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The director acknowledges her responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The company has taken advantage of section 444(1) of the Companies Act 2006 and opted not to deliver to the registrar a copy of the company's Profit and Loss Account.

On behalf of the board

Mrs Fatemah Ali Moledina

Director

06/06/2025

The notes on pages 3 to 5 form part of these financial statements.

1. General Information

NS Pharma Limited is a private company, limited by shares, incorporated in England & Wales, registered number 09792259 . The registered office is 193 Edgware Road, London, NW9 6LP.

2. Accounting Policies

2.1. Basis of Preparation of Financial Statements

The financial statements have been prepared under the historical cost convention and in accordance with Financial Reporting Standard 102 section 1A Small Entities "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006.

2.2. Turnover

Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services. Turnover is reduced for estimated customer returns, rebates and other similar allowances.

Sale of goods

Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods has transferred to the buyer. This is usually at the point that the customer has signed for the delivery of the goods.

Rendering of services

Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs. Turnover is only recognised to the extent of recoverable expenses when the outcome of a contract cannot be estimated reliably.

2.3. Intangible Fixed Assets and Amortisation - Goodwill

Goodwill is the difference between amounts paid on the acquisition of a business and the fair value of the separable net assets. It is amortised to the profit and loss account over its estimated economic life of .... years.

2.4. Stocks and Work in Progress

Stocks and work in progress are valued at the lower of cost and net realisable value after making due allowance for obsolete and slow-moving stocks. Cost includes all direct costs and an appropriate proportion of fixed and variable overheads. Work-in-progress is reflected in the accounts on a contract by contract basis by recording turnover and related costs as contract activity progresses.

3. Average Number of Employees

Average number of employees, including directors, during the year was: 2 (2023: 2)

Page 3

Page 4

NS Pharma Limited

Notes to the Financial Statements (continued)

For The Year Ended 30 September 2024

4. Intangible Assets

	Goodwill
	£
Cost
As at 1 October 2023	500,000

As at 30 September 2024	500,000

Amortisation
As at 1 October 2023	350,000
Provided during the period	50,000

As at 30 September 2024	400,000

Net Book Value
As at 30 September 2024	100,000

As at 1 October 2023	150,000

5. Stocks

	2024	2023
	£	£
Stock	50,570	42,570

6. Debtors

	2024	2023
	£	£
Due within one year
Trade debtors	44,488	47,943
Other debtors	35,655	31,736

	80,143	79,679

7. Creditors: Amounts Falling Due Within One Year

	2024	2023
	£	£
Trade creditors	55,913	-
Amounts owed to participating interests	46,975	101,613
Other creditors	19,841	32,230
Taxation and social security	84,280	59,256

	207,009	193,099

Page 4

Page 5

NS Pharma Limited

Notes to the Financial Statements (continued)

For The Year Ended 30 September 2024

8. Creditors: Amounts Falling Due After More Than One Year

	2024	2023
	£	£
Bank loans	39,333	39,333
Other creditors	334,994	334,994

	374,327	374,327

9. Share Capital

	2024	2023
	£	£
Allotted, Called up and fully paid	2	2

Page 5